전체메뉴 닫기
진료예약·상담
진료일정
진료예약

진료예약 안내

처음진료 빠른예약

건강검진 예약상담

전화예약

방문예약

FAX예약

예약조회·취소

1:1전문의상담

진료과별 상담

이용안내 FAQ

고마워요 차병원
진료과·의료진
센터·진료과 찾기

센터 리스트

진료과 리스트

클리닉 리스트

진료과·의료진 검색

쉬운 진료과 찾기

질환별 찾기

진료과별 FAQ

산부인과 FAQ

소아청소년과 FAQ

비뇨의학과 FAQ

이용안내
처음오시는분
외래·응급·입원

외래진료안내

응급진료안내

건강보험안내

입퇴원·면회안내

입원생활안내

비급여수가안내
병원 층별 안내
편의시설

상가 B1

상가 1F

상가 2F

상가 3F

주요전화번호
증명서발급안내

진단서 및 증명서

의무기록사본

온라인 신청

찾아오시는길

약도·자가용

대중교통안내

주차안내

고객의 소리
산후조리원

소개

산후조리 서비스

SPA

상생의원

성형외과·피부과

정형외과

치과

건강정보
건강강좌

이달의 건강강좌

산모대학 무료공개강좌

태교학교

육아교실

난임교실

생애주기 여성건강교실

건강라이프 칼럼
CHA 유튜브
건강한 출산 A to Z

임신준비관리

산전관리

분만관리

산후관리

아기관리

항상 최고의 진료를
약속합니다

산부인과(부인종양센터) 노주원 교수

일반진료
오전 진료 진료 2,4주
오후 진료 진료 진료

전문분야

부인암, 복막암, 부인과 양성질환(양성종양, 자궁내막증, 자궁선근증), 부인과 내시경수술(로봇수술, 복강경수술, 자궁경수술), 자궁선근증감축술

교수 경력

  • 서울대학교
  • 동국대학교
  • 차의과학대학교

진료 경력

  • MD Anderson Cancer Center
  • 국립암센터
  • 일산동국대학교병원 산부인과 진료과장
  • 차의과학대학교 일산차병원 산부인과
  • 차의과학대학교 일산차병원 부인종양센터

학회·연구·연수·수상 경력

  • 독일 Friedrich-Schiller University 부인종양학 연수
  • 독일 Leipzig University 부인종양학 연수
  • 제 41차 대한암학회 노바티스 Merit award (2015)
  • 제 39차 대한암학회 학술대회 GSK학술상 (2013)
  • Merit Award, in the 10th International Conference of ACOS(2012)

  • 언론기사·영상
  • 논문
  1. Safety and effective of dienogest (Visanne®) for treatment of endometriosis: a large prospective cohort study. Reprod Sci (in publication)
  2. Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther 2019;20:1-10. doi: 10.1080/15384047
  3. Type-specific viral load and physical state of HPV type 16, 18, and 58 as diagnostic biomarkers for high-grade squamous intraepithelial lesions or cervical cancer. Cancer Res Treat 2019; (In publication)
  4. Practice guidelines for management of ovarian cancer in Korea: A Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol 2018;29(4):e56
  5. Surg Endosc 2018;32:2643-2649
  6. Surgical manual of the Korean Gynecologic Oncology Group: Classification of hysterectomy and lymphadenectomy. J Gynecol Oncol 2017;28(1):e5.
  7. Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial. J Gynecol Oncol, 2015;26(2) :90-99.
  8. Factors Affecting Unused Remaining Volume of Intravenous Patient-controlled Analgesia in Patients Following Laparoscopic Gynecologic Surgery. Asian Nursing Research 2014 Dec8:300-4.
  9. Biological effects of platelet-derived growth factor receptor α blockade in uterine cancer. Clin Cancer Res 2014;May 15;20(10): 2740-50.
  10. Crosstalk between EphA2 and Braf/Craf is a key determinant of response to Dasatinib. Clin Cancer Res 2014 Apr:;20(7):1846-55.
  11. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol 2014;Jan;132(1)166-75.
  12. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia .2013May;15(5):502-10.
  13. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol 2013 Feb;128(2); 344-8.
  14. Clinical and biological relevance of enhancer of zeste homolog 2 in triple negative breast cancer. Human Pathol 2012;43(10):1638-44.
  15. Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. Int J Gynecol Cancer 2012;22:1570-1576.
  16. A novel platform for detection of CK+ and CK- CTCs. Cancer Discovery 2011;1(7):580-586.
  17. Biological roles of the Delta family notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res.2011;71:6030-6039.
  18. Targeting Src in Mucinous Ovarian Carcinoma. Clin Cancer Res. 2011; 17 (16):5367-78.
  19. A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of a far infrared-emitting sericite belt in patients with primary dysmenorrhea. Complement Ther Med 2011Aug;19(4):187-93
  20. Diastolic forward flow in the fetal main pulmonary artery and its implication for fetal cardiac cycle evaluation. J Perinat Med 2011.2011;39:445-450.
  21. Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer 2011;21(4):668-672.
  22. Chitosan hydrogel for localized gene silencing. CancerBiolTher2011;11:839-845.
  23. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011 Apr;13(4):309-19.
  24. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res . 2011 Apr 1:17(7):1713-1721.
  25. Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. Clin Cancer Res 2010;16(15):3910-22.
  26. p53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res 2010;18(9):453-9.
  27. EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma. Clin Cancer Res; 2010;16(9) May: 2562–70.
  28. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol 2009 Oct20; 27(30): 5088-93.
  29. Successful twin pregnancy after vaginal radical trachelectomy using transabdominal cervicoisthmic cerclage. Am J Obstet Gynecol 2007;197(3):e5-6.
  30. Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. Cancer Sci 2007;98:329-333.
  31. Validation study of the Korean version of the M.D. Anderson Symptom Inventory. J Pain Symptom Manag.2006;Apr;31(4):345-52.
  32. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol 2006;132(5):302-8.
  33. Comparison of accuracies of MRI and PET/CT in presurgical detection of lymph node metastases in patients with uterine cervical cancer: a prospective study. Cancer2006;106(4):914-22.
  34. Single nucleotide polymorphism: a new risk factor for endometrial cancer? Future Oncol 2005;1(3):323-30.
  35. Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study. Eur J Cancer 2005;41(14):2086-92.
  36. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol I 2005;32:757-763.
  37. Pretreatment laparoscopic surgical staging in locally advanced cervical cancer: Preliminary results in Korea. Gynecol Oncol 2005;97(2):468-475.
  38. Validation Study of the Korean Version of the Bried Fatigue Inventory. J Pain Symptom Manag 2005;29:165-172.
  39. Prevalence and Determinants of Genital Infection with Papillomavirus, in Female and Male University. J Infect Dis 2004;190:468-76.
  40. p53 and p21 genetic polymorphism and susceptibility to endometrial cancer. Gynecol Oncol 2004;93:499-505.
  41. Genetic polymorphism of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol Oncol 2004;93:14-18.
  42. Interferon, alpha 17 (IFNA17) Ile 184Arg polymorphism and cervical cancer risk. Cancer Lett 2003;189:183-8.
  43. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett 2002;184:57-63.
  44. A comparison of the therapeutic efficacies of large loop excision of the transformation zone (LLETZ) and hysterectomy for the treatment of cervical intraepithelial neoplasia (CIN) III. Int J Gynecol Cancer 2001;11:387-391.
  45. Polymorphism in Codon 31 of p21 and Cervical Cancer Susceptibility in Korean women. Cancer Lett 2001;165:59-62.
  46. Polymorphism of p53 codon 72 and the risk of cervical cancer in Korean women. Am J Obstet Gynecol 2001;184:55-8.